Clinical Trials on Recurrent Borderline Ovarian Surface Epithelial-stromal Tumor in France

Total 153 results

ARCAGY/ GINECO GROUP
Roche Pharma AG

Completed

Efficacy and Safety of Bevacizumab (Avastin®) Combined to Weekly Paclitaxel Followed by Bevacizumab (Avastin®) Alone in Patients With Relapsed Ovarian Sex-cord Stromal Tumours (ALIENOR) (ALIENOR)

Ovarian Sex-cord Stromal Tumor

France
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Collecting Tumor Samples From Patients With Gynecological Tumors

Melanoma | Malignant Mesothelioma | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Serous Cystadenocarcinoma | Gestational Trophoblastic Tumor | Cervical Adenocarcinoma and other conditions

United States
Centre Oscar Lambret
Canceropôle Nord Ouest; Groupement Interrégional de Recherche Clinique et d...

Recruiting

Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring (SUR-CAN)

Glioma | Gastrointestinal Stromal Tumors | Neuroendocrine Tumors | Adenocarcinoma, Clear Cell | Carcinoma, Small Cell | Ovarian Germ Cell Tumor | Stage I Testicular Seminoma | Stage I Testicular Nonseminomatous Germ Cell Tumor | Borderline Ovarian Tumor | Sex Cord-Stromal Tumor | Mucinous Adenocarcinoma of... and other conditions

France
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

Ovarian Serous Adenocarcinoma | Primary Peritoneal Serous Adenocarcinoma | Recurrent Ovarian Low Grade Serous Adenocarcinoma | Borderline Ovarian Serous Tumor | Micropapillary Serous Carcinoma | Recurrent Primary Peritoneal Serous Adenocarcinoma

United States, United Kingdom
Centre Francois Baclesse
ARCAGY/ GINECO GROUP

Active, not recruiting

Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of Chemotherapy (VIVROVAIRE TR)

Germ Cell Tumor | Sex Cord Stromal Tumor | Malignant Non-epithelial Ovarian Tumors

France
National Cancer Institute (NCI)
NRG Oncology

Completed

Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation Carrier | Ovarian Epithelial Tumor

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer

Recurrent Ovarian Carcinoma | Malignant Ovarian Clear Cell Tumor

United States, Puerto Rico
Institut Curie
ARCAGY/ GINECO GROUP

Completed

Study Describing the Coverage, Cares and the Fertility of Patients of Less Than 45 Years With a Borderline Ovarian Tumor (OPTIBOT)

Borderline Ovarian Tumors

France
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Paclitaxel in Treating Patients With Ovarian Stromal Cancer

Adult Type Ovarian Granulosa Cell Tumor | Ovarian Gynandroblastoma | Ovarian Sertoli-Leydig Cell Tumor | Ovarian Sex Cord Tumor With Annular Tubules | Ovarian Steroid Cell Tumor

United States, Japan
Assistance Publique - Hôpitaux de Paris

Active, not recruiting

Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation (AGIR)

Recurrent IDH1/2 Mutated Glioma

France
Sanofi

Completed

Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel (OPSALIN)

Ovarian Cancer Recurrent

Belgium, Russian Federation, Poland, Spain, Czech Republic, United States, France, Germany, Italy, Ukraine
AGO Research GmbH
Hoffmann-La Roche

Active, not recruiting

Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

Recurrent Ovarian Carcinoma

Norway, Spain, France, Switzerland, Denmark, Germany, Sweden, Belgium, Finland, Austria, Estonia, Lithuania
Universitaire Ziekenhuizen KU Leuven
Eli Lilly and Company; European Network of Gynaecological Oncological Trial... and other collaborators

Recruiting

Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer (ALEPRO)

Low Grade Serous Ovarian Carcinoma | Adult Type Granulosa Cell Tumor

Belgium, Netherlands, France
AstraZeneca
Merck Sharp & Dohme LLC; Myriad Genetic Laboratories, Inc.

Completed

Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer (CONCERTO)

Recurrent Platinum Resistant Ovarian Cancer

United States
ARCAGY/ GINECO GROUP

Completed

Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse

Ovarian Cancer | Fallopian Tube Cancer | Malignant Tumor of Peritoneum

France
Hospices Civils de Lyon

Completed

Olaparib in Recurrent IDH-mutant Glioma (OLAGLI)

Recurrent IDH | Mutant High Grade Glioma

France
Assistance Publique - Hôpitaux de Paris

Completed

Treatment With AZD4547 for Recurrent Malignant Glioma Expressing FGFR-TACC Gene Fusion" (TARGET)

Recurrent IDHwt Gliomas With FGFR3-TACC3 Fusion | Recurrent IDHwt Gliomas With FGFR1-TACC1 Fusion

France
Medical University of Vienna

Recruiting

Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma and ATRT (MEMMAT)

Medulloblastoma Recurrent | Ependymoma Recurrent | ATRT Recurrent

Austria, Sweden, France, Spain, United States, Czechia, Denmark, Norway
ARCAGY/ GINECO GROUP

Completed

A 2 Stage Trial of Lenalidomide (REV) in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse (REV)

Ovarian Cancer Recurrent

France
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Ovarian Undifferentiated Carcinoma

United States
National Cancer Institute (NCI)
AstraZeneca; NRG Oncology

Active, not recruiting

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian... and other conditions

United States, Canada, Korea, Republic of, Japan
Vascular Biogenics Ltd. operating as VBL Therapeutics
GOG Foundation

Completed

A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL) (OVAL)

Recurrent Platinum Resistant Ovarian Cancer

United States, Israel, Japan, Poland, Spain
AstraZeneca
RTI Health Solutions; A+A Healthcare Marketing Research; Freelance CRA (FCRA)

Completed

OSCA - Olaparib Standard of CAre Study (OSCA)

Platinum-sensitive Recurrent Serous Ovarian Cancer

France, Italy, Korea, Republic of, Spain, United Kingdom, Germany, Belgium, Israel, Portugal, Netherlands, Switzerland, Canada, Australia
ZIWIG
Monitoring Force Group; iGenSeq

Recruiting

Evaluation of Salivary RNAs in the Presence of an Adnexal Mass of Ovarian Origin (OVAmiARN)

Ovarian Cancer | Ovarian Cyst Benign | Borderline Ovarian Cancer

France
Regeneron Pharmaceuticals

Recruiting

Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

Recurrent Endometrial Cancer | Recurrent Ovarian Cancer | Recurrent Fallopian Tube Cancer | Recurrent Primary Peritoneal Cancer

United States, Spain, Korea, Republic of, Italy, United Kingdom, Netherlands, Belgium, Australia, France, Israel
AGO Research GmbH
ARCAGY/ GINECO GROUP; Australia New Zealand Gynaecological Oncology Group; Arbeitsgemeinschaft... and other collaborators

Completed

Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer

Recurrent Platinum-sensitive Ovarian Cancer

France, Belgium, Germany, Australia, United Kingdom, Austria
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Primary Peritoneal Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Malignant Ovarian Endometrioid Tumor | Ovarian High Grade Serous Adenocarcinoma | Platinum-Sensitive Ovarian Carcinoma | Fallopian Tube High Grade Serous Adenocarcinoma and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Ovarian High Grade Serous Adenocarcinoma | Fallopian... and other conditions

United States, Puerto Rico
Centre Leon Berard

Completed

Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (ImadGist)

Gastrointestinal Stromal Tumors | Resected Gastrointestinal Stromal Tumors | Non-metastatic | High Risk of Recurrence | KIT Gene Mutation

France
Gustave Roussy, Cancer Campus, Grand Paris

Unknown

Trial Comparing Simple Follow-up to Exploratory Laparotomy Plus "in Principle" (Hyperthermic Intraperitoneal Chemotherapy) HIPEC in Colorectal Patients (ProphyloCHIP)

Colorectal Cancer With a Resected Minimal Synchronous PC | Ovarian Metastases | Tumour Rupture in the Abdominal Cavity

France
GOG Foundation
National Cancer Institute (NCI)

Completed

Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
Aprea Therapeutics

Completed

p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246

Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53

United States, France, Spain, Netherlands, United Kingdom, Belgium, Germany, Sweden
National Cancer Institute (NCI)

Recruiting

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

Malignant Solid Neoplasm | Rhabdoid Tumor | Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Rhabdoid Tumor | Refractory Rhabdoid Tumor | Epithelioid Sarcoma | Kidney Medullary Carcinoma | Atypical Teratoid/Rhabdoid Tumor | Poorly Differentiated Chordoma | Recurrent Atypical... and other conditions

United States, Australia, Canada
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer

Recurrent Ovarian Carcinoma | Recurrent Endometrial Endometrioid Adenocarcinoma | Recurrent Uterine Corpus Cancer | Recurrent Ovarian Clear Cell Adenocarcinoma | Recurrent Ovarian Endometrioid Adenocarcinoma

United States
ARCAGY/ GINECO GROUP

Active, not recruiting

Tri Association in Patient With Advanced Epithelial Ovarian Cancer in Relapse (BOLD)

Epithelial Ovarian Cancer | Relapse

France
Institut Paoli-Calmettes
AstraZeneca

Recruiting

Circulating Tumor DNA as an Early Marker of Recurrence and Treatment Efficacy in Ovarian Carcinoma (CIDOC)

Ovarian Carcinoma

France
GlaxoSmithKline

Completed

Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors

Cancer | Epithelial Ovarian Cancer | Tumor | Primary Peritoneal Carcinoma | Neoplasms, Ovarian | Uterine Disease | Cervix Diseases

France, Germany
National Cancer Institute (NCI)

Completed

Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies

Recurrent Malignant Solid Neoplasm | Childhood Solid Neoplasm | Recurrent Childhood Central Nervous System Neoplasm | Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Adult Solid Neoplasm | Refractory Central Nervous System Neoplasm

United States
Imagine Institute

Recruiting

Juvenile Recurrent Respiratory Papillomatosis: Establishment of a French National Cohort (PRR : National Cohort " REPA ") (REPA)

Juvenile Recurrent Respiratory Papillomatosis

France
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Ovarian Seromucinous Carcinoma | Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Fallopian Tube Mucinous Adenocarcinoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Fallopian Tube Endometrioid Adenocarcinoma | Recurrent... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)

Completed

Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors

Pineoblastoma | Recurrent Medulloblastoma | Refractory Medulloblastoma | Refractory Peripheral Primitive Neuroectodermal Tumor | Central Nervous System Neoplasm | Recurrent Primitive Neuroectodermal Tumor

United States, Canada, Puerto Rico, Australia, New Zealand
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia

Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Recurrent Neuroblastoma | Recurrent Osteosarcoma | Hepatoblastoma | Recurrent Childhood Rhabdomyosarcoma | Recurrent Childhood Kidney Neoplasm | Previously Treated Childhood Rhabdomyosarcoma | Recurrent Childhood... and other conditions

United States, Canada
Institut Bergonié

Unknown

MOLecular Characterization and Treatment of THYroid Carcinoma on Struma Ovarii (MOLTHYSO)

Ovarian Cancer

France
ARCAGY/ GINECO GROUP
European Organisation for Research and Treatment of Cancer - EORTC; Scherin... and other collaborators

Completed

Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse (CALYPSO)

Ovarian Cancer | Fallopian Tube Cancer

France
National Cancer Institute (NCI)

Completed

Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Refractory Malignant Solid Neoplasm | Pineoblastoma | Recurrent Malignant Solid Neoplasm | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent Rhabdomyosarcoma | Refractory Medulloblastoma | Refractory Neuroblastoma | Refractory Rhabdomyosarcoma | Central Nervous System Embryonal Tumor With... and other conditions

United States, Canada
Novartis Pharmaceuticals

Completed

Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme

Recurrent Glioblastoma Multiforme

United States, Belgium, Australia, Spain, France, Canada
UNICANCER

Active, not recruiting

Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment (CHIPOR)

Ovarian Epithelial Cancer Recurrent

France, Belgium, Spain
National Cancer Institute (NCI)

Active, not recruiting

Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

Recurrent Childhood Ependymoma | Advanced Malignant Solid Neoplasm | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent Non-Hodgkin... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma

Recurrent Glioblastoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Malignant Solid Neoplasm | Recurrent Melanoma | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent Non-Hodgkin... and other conditions

United States, Puerto Rico

Clinical Trials on Recurrent Borderline Ovarian Surface Epithelial-stromal Tumor in France

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Croatia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations